Literature DB >> 21056473

Lipidation of intact proteins produces highly immunogenic vaccine candidates.

Weiguang Zeng1, Emily M Eriksson, Andrew Lew, David C Jackson.   

Abstract

In this study we investigate the feasibility of generating self-adjuvanting vaccines capable of inducing high titre antibody responses following the covalent attachment of the TLR2 agonist Pam(2)Cys to intact proteins. Three Pam(2)Cys-based lipid moieties were prepared which contain a solubilising spacer composed of either lysine residues or polyethyleneglycol. A model protein, hen egg white lysozyme (HEL), was lipidated individually with each of these lipid modules and the immunogenicity of the lipidated species studied in mice by measuring antibody responses. We found that lipidated HEL elicited antibodies which is much stronger than the responses obtained when the HEL was administered in Freund's adjuvant or in Alum. Little or no antibody was elicited by the lipidated HEL in CD4 T cell-deficient mice indicating that the antibody response is T cell dependent. Furthermore, the lipidated protein elicited similar antibody responses in two different strains of mice indicating that sufficient helper T cell epitopes are available to enable antibody production across the histocompatability barrier. In a similar way, lipidated bovine insulin was found to be highly immunogenic in mice despite the largely conserved sequences of bovine and murine insulin. The results provide evidence that lipidation of proteins provides a simple and safe method for the manufacture of soluble self-adjuvanting protein-based vaccines. Crown
Copyright © 2010. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056473     DOI: 10.1016/j.molimm.2010.10.003

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

1.  A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building.

Authors:  Weiguang Zeng; Kylie J Horrocks; Gorjana Robevska; Chinn Yi Wong; Kristy Azzopardi; Marija Tauschek; Roy M Robins-Browne; David C Jackson
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

Review 2.  Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.

Authors:  Isabelle Legastelois; Sophie Buffin; Isabelle Peubez; Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Hum Vaccin Immunother       Date:  2016-12-01       Impact factor: 3.452

3.  Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines.

Authors:  Nikunj M Shukla; Tyler C Lewis; Timothy P Day; Cole A Mutz; Rehman Ukani; Chase D Hamilton; Rajalakshmi Balakrishna; Sunil A David
Journal:  Bioorg Med Chem Lett       Date:  2011-04-20       Impact factor: 2.823

4.  Different arms of the adaptive immune system induced by a combination vaccine work in concert to provide enhanced clearance of influenza.

Authors:  Joanna C A Cobbin; Weiguang Zeng; David C Jackson; Lorena E Brown
Journal:  PLoS One       Date:  2014-12-18       Impact factor: 3.240

5.  The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells.

Authors:  Xueheng Guo; Ning Wu; Yingli Shang; Xin Liu; Tao Wu; Yifan Zhou; Xin Liu; Jiaoyan Huang; Xuebin Liao; Li Wu
Journal:  Front Immunol       Date:  2017-02-21       Impact factor: 7.561

Review 6.  Targeting TLR2 for vaccine development.

Authors:  Afonso P Basto; Alexandre Leitão
Journal:  J Immunol Res       Date:  2014-06-26       Impact factor: 4.818

Review 7.  Cognizance of posttranslational modifications in vaccines: A way to enhanced immunogenicity.

Authors:  Rupal Ojha; Vijay Kumar Prajapati
Journal:  J Cell Physiol       Date:  2021-06-25       Impact factor: 6.513

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.